Coagulation Disorders in the PICU

  • Geoffrey M. Fleming
  • Gail M. Annich


Critically ill patients often have alterations in the hemostatic milieu that require the pediatric intensivist to evaluate and treat clinical changes. Sometimes these alterations may be the primary clinical issue as seen in congenital factor deficiencies but more commonly are acquired and secondary to other systemic illnesses as is the case in disseminated intravascular coagulation. The goal of this chapter is to provide background into the normal components and function (both procoagulant and anticoagulant) of the hemostatic system including coagulation factors, platelets, thrombus formation and fibrinolysis. Using this background information, frequently encountered pathophysiologic clinical scenarios are reviewed including etiology and therapeutic options.


Disseminated intravascular coagulation (DIC) Coagulation cascade Prothrombin time Activated partial thromboplastin time Thromboelastography (TEG) 


  1. 1.
    Giangrande PLF. Six characters in search of an author: the history of the nomenclature of coagulation factors. Br J Haematol. 2003;121:703–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25:5681–703.PubMedCrossRefGoogle Scholar
  3. 3.
    Rao G. Platelet physiology and pharmacology: an overview. In: Rao G, editor. Handbook of platelet physiology and pharmacology. 1st ed. Norwell: Kluwer Academic Publishers; 1999. p. 1–20.CrossRefGoogle Scholar
  4. 4.
    Marcus A. Platelet activation. In: Fuster V, Ross R, Topol EJ (eds.), Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven; 1996. p. 607–37.Google Scholar
  5. 5.
    Fromjmovic M. Platelet biorheology: adhesive interactions in flow. In: Rao G, editor. Handbook of platelet physiology and pharmacology. Norwell: Kluwer; 1999. p. 315–41.CrossRefGoogle Scholar
  6. 6.
    Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol. 1987;92:639–46.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Radomski M, Moncada S. The biological and pharmacological role of nitric oxide in platelet function. In: Authi KS, (ed), Mechanisms of platelet activation and control. New York: Plenum Press; 1993. p. 251–64.CrossRefGoogle Scholar
  8. 8.
    Saadi S, Platt J. Endothelial cell responses to complement activation. In: Volanakis J, Frank M, (eds.), The human complement system in health and disease. New York: Marcel Dekker INC; 1998. p. 335–53.CrossRefGoogle Scholar
  9. 9.
    Niewiarowski S, Senyi AF, Gillies P. Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. J Clin Invest. 1973;52:1647–59.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Wenger RK, Lukasiewicz H, Mikuta BS, Niewiarowski S, Edmunds LH. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1989;97:235–9.PubMedGoogle Scholar
  11. 11.
    Downing SW, Edmunds LH. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg. 1992;54:1236–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Vane JR, Anggård EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27–36.PubMedCrossRefGoogle Scholar
  13. 13.
    Jaffe E. Endothelial cell structure and function. In: Hoffman R, Benz E, Shattil S, (eds.), Hematology, basic principles and practice. New York: Churchill Livingstone; 1991. p. 1198–213.Google Scholar
  14. 14.
    Colman R, Clowes A, George J, Hirsch J, Marder V. Overview of hemostasis. In: Colman R, Hirsch J, Marder V, Clowes A, George J, (eds.), Hemostatis and thrombosis; basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 3–16.Google Scholar
  15. 15.
    Colman RW. Biologic activities of the contact factors in vivo–potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb Haemost. 1999;82:1568–77.PubMedGoogle Scholar
  16. 16.
    Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000;95:543–50.PubMedGoogle Scholar
  17. 17.
    Mandle RJ, Colman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci U S A. 1976;73:4179–83.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Colman RW. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest. 1984;73:1249–53.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Colman R. Contact activation pathway: inflammatory, fibrinolytic, anticoagulant, antiadhesive and antiangiogenic activities. In: Colman R, Clowes A, George J, Hirsch J, Marder V, (eds.), Hemostasis and thrombosis; basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 103–21.Google Scholar
  20. 20.
    Gigli I, Mason JW, Colman RW, Austen KF. Interaction of plasma kallikrein with the C1 inhibitor. J Immunol. 1970;104:574–81.PubMedGoogle Scholar
  21. 21.
    Schapira M, Scott CF, Colman RW. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors. Trans Assoc Am Physicians. 1981;94:190–7.PubMedGoogle Scholar
  22. 22.
    Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 1990;76:731–6.PubMedGoogle Scholar
  23. 23.
    Limentani S, Furie B, Furie B. The biochemistry of factor IX. In: Colman R, Hirsch J, Marder V, Salzman E, (eds.), Hemostasis and thrombosis; basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1994. p. 94–108.Google Scholar
  24. 24.
    Schapira M, Scott CF, James A, et al. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry. 1982;21:567–72.PubMedCrossRefGoogle Scholar
  25. 25.
    Tracy PB, Eide LL, Mann KG. Human prothrombinase complex assembly and function on isolated peripheral blood cell populations. J Biol Chem. 1985;260:2119–24.PubMedGoogle Scholar
  26. 26.
    Tracy PB, Rohrbach MS, Mann KG. Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem. 1983;258:7264–7.PubMedGoogle Scholar
  27. 27.
    Edwards RL, Rickles FR. Macrophage procoagulants. Prog Hemost Thromb. 1984;7:183–209.PubMedGoogle Scholar
  28. 28.
    Scandura JM, Walsh PN. Factor X bound to the surface of activated human platelets is preferentially activated by platelet-bound factor IXa. Biochemistry. 1996;35:8903–13.PubMedCrossRefGoogle Scholar
  29. 29.
    Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618–23.PubMedCrossRefGoogle Scholar
  30. 30.
    Colucci M, Balconi G, Lorenzet R, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest. 1983;71:1893–6.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Coughlin SR, Vu TK, Hung DT, Wheaton VI. Characterization of a functional thrombin receptor. Issues and opportunities. J Clin Invest. 1992;89:351–5.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol. 1989;109:389–95.PubMedCrossRefGoogle Scholar
  33. 33.
    Grabowski E, Rodriguez M, Nemerson Y, McDonnell S. Flow limits factor Xa production by monolayers of fibroblasts and endothelial cells. Blood. 1990;76(Supp):422a.Google Scholar
  34. 34.
    Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 1991;66:67–79.PubMedGoogle Scholar
  35. 35.
    Francis C, Marder V. Physiologic regulation and pathologic disorders of fibrinolysis. In: Colman R, Hirsch J, Marder V, Salzman E, (eds.), Hemostasis and thrombosis; basic principles and clinical practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1994. p. 1076–103.Google Scholar
  36. 36.
    Urlesberger B, Zobel G, Zenz W, et al. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr. 1996;129:264–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Lu H, Soria C, Cramer EM, et al. Temperature dependence of plasmin-induced activation or inhibition of human platelets. Blood. 1991;77:996–1005.PubMedGoogle Scholar
  38. 38.
    Lu H, Du Buit C, Soria J, et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost. 1994;72:438–43.PubMedGoogle Scholar
  39. 39.
    Nurmohamed MT, ten Cate H, ten Cate JW. Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations. Drugs. 1997;53:736–51.PubMedCrossRefGoogle Scholar
  40. 40.
    Berger M. Complement mediated phagocytosis. In: Volanakis J, Frank M, (eds.), The human complement system in health and disease. New York: Marcel Dekker Inc; 1998. p. 285–308.CrossRefGoogle Scholar
  41. 41.
    Chenoweth DE, Hugli TE. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1978;75:3943–7.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Volanakis J. Overview of the complement system. In: Volanakis J, Frank M, (eds.), The human complement system in health and disease. New York: Marcel Dekker Inc; 1998. p. 9–32.CrossRefGoogle Scholar
  43. 43.
    Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986;68:875–80.PubMedGoogle Scholar
  44. 44.
    Cameron D. Initiation of white cell activation during cardiopulmonary bypass: cytokines and receptors. J Cardiovasc Pharmacol. 1996;27 Suppl 1:S1–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Cristol JP, Canaud B, Rabesandratana H, Gaillard I, Serre A, Mion C. Enhancement of reactive oxygen species production and cell surface markers expression due to haemodialysis. Nephrol Dial Transplant. 1994;9:389–94.PubMedGoogle Scholar
  46. 46.
    el Habbal MH, Carter H, Smith LJ, Elliott MJ, Strobel S. Neutrophil activation in paediatric extracorporeal circuits: effect of circulation and temperature variation. Cardiovasc Res. 1995;29:102–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100:2499–506.PubMedCrossRefGoogle Scholar
  48. 48.
    Gillinov AM, Bator JM, Zehr KJ, et al. Neutrophil adhesion molecule expression during cardiopulmonary bypass with bubble and membrane oxygenators. Ann Thorac Surg. 1993;56:847–53.PubMedCrossRefGoogle Scholar
  49. 49.
    Rinder C, Fitch J. Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. J Cardiovasc Pharmacol. 1996;27 Suppl 1:S6–12.PubMedCrossRefGoogle Scholar
  50. 50.
    Rousseau Y, Carreno MP, Poignet JL, Kazatchkine MD, Haeffner-Cavaillon N. Dissociation between complement activation, integrin expression and neutropenia during hemodialysis. Biomaterials. 1999;20:1959–67.PubMedCrossRefGoogle Scholar
  51. 51.
    Videm V, Mollnes TE, Fosse E, et al. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg. 1999;117:794–802.PubMedCrossRefGoogle Scholar
  52. 52.
    von Appen K, Goolsby C, Mehl P, Goewert R, Ivanovich P. Leukocyte adhesion molecules as biocompatibility markers for hemodialysis membranes. ASAIO J. 1994;40:M609–15.CrossRefGoogle Scholar
  53. 53.
    Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med. 1977;296:769–74.PubMedCrossRefGoogle Scholar
  54. 54.
    Wachtfogel YT, Kucich U, Greenplate J, et al. Human neutrophil degranulation during extracorporeal circulation. Blood. 1987;69:324–30.PubMedGoogle Scholar
  55. 55.
    Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg. 1998;66:2135–44.PubMedCrossRefGoogle Scholar
  56. 56.
    Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation. 1996;93:2014–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor. Thromb Res. 1996;83:307–20.PubMedCrossRefGoogle Scholar
  58. 58.
    Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg. 1997;113:576–84.PubMedCrossRefGoogle Scholar
  59. 59.
    Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault K, Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology. 1991;75:388–93.PubMedCrossRefGoogle Scholar
  60. 60.
    Insel P. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman J, Limbird L, (eds.), Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill Inc; 1996. p. 618–9.Google Scholar
  61. 61.
    Fingerle-Rowson G, Auers J, Kreuzer E, et al. Down-regulation of surface monocyte lipopolysaccharide-receptor CD14 in patients on cardiopulmonary bypass undergoing aorta-coronary bypass operation. J Thorac Cardiovasc Surg. 1998;115:1172–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Haeffner-Cavaillon N, Roussellier N, Ponzio O, et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1989;98:1100–6.PubMedGoogle Scholar
  63. 63.
    Greaves M, Preston F. Approach to the bleeding patient. In: Colman R, Hirsch J, Marder V, Clowes A, George J, (eds.), Hemostasis and thrombosis; basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 783–93.Google Scholar
  64. 64.
    Flanders MM, Crist RA, Roberts WL, Rodgers GM. Pediatric reference intervals for seven common coagulation assays. Clin Chem. 2005;51:1738–42.PubMedCrossRefGoogle Scholar
  65. 65.
    Hartert H. Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klin Wochenschr. 1948;26:577–83.PubMedCrossRefGoogle Scholar
  66. 66.
    Reikvam H, Steien E, Hauge B, et al. Thrombelastography. Transfus Apher Sci. 2009;40:119–23.PubMedCrossRefGoogle Scholar
  67. 67.
    MacDonald SG, Luddington RJ. Critical factors contributing to the thromboelastography trace. Semin Thromb Hemost. 2010;36:712–22.PubMedCrossRefGoogle Scholar
  68. 68.
    Chitlur M, Lusher J. Standardization of thromboelastography: values and challenges. Semin Thromb Hemost. 2010;36:707–11.PubMedCrossRefGoogle Scholar
  69. 69.
    Bernabei A, Gikakis N, Maione TE, et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1995;109:765–71.PubMedCrossRefGoogle Scholar
  70. 70.
    Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–91.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost. 1993;70:259–62.PubMedGoogle Scholar
  72. 72.
    Ellison N, Edmunds LH, Colman RW. Platelet aggregation following heparin and protamine administration. Anesthesiology. 1978;48:65–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest. 1991;87:1787–93.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Pixley RA, Cassello A, De La Cadena RA, Kaufman N, Colman RW. Effect of heparin on the activation of factor XII and the contact system in plasma. Thromb Haemost. 1991;66:540–7.PubMedGoogle Scholar
  75. 75.
    Cavarocchi NC, Schaff HV, Orszulak TA, Homburger HA, Schnell WA, Pluth JR. Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass. Surgery. 1985;98:525–31.PubMedGoogle Scholar
  76. 76.
    Kirklin JK, Chenoweth DE, Naftel DC, et al. Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. Ann Thorac Surg. 1986;41:193–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Wachtfogel YT, Harpel PC, Edmunds LH, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood. 1989;73:468–71.PubMedGoogle Scholar
  78. 78.
    Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1–17.PubMedGoogle Scholar
  79. 79.
    Gikakis N, Rao AK, Miyamoto S, et al. Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg. 1998;116:1043–51.PubMedCrossRefGoogle Scholar
  80. 80.
    Wolzt M, Weltermann A, Nieszpaur-Los M, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost. 1995;73:439–43.PubMedGoogle Scholar
  81. 81.
    Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med. 1999;50:129–47.PubMedCrossRefGoogle Scholar
  82. 82.
    Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 1983;258:6713–6.PubMedGoogle Scholar
  83. 83.
    Gillis S, Merin G, Zahger D, et al. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haematol. 1997;98:657–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Harker LA. Therapeutic inhibition of thrombin activities, receptors, and production. Hematol Oncol Clin North Am. 1998;12:1211–30.PubMedCrossRefGoogle Scholar
  85. 85.
    ONLINE™ L-C. Lexi-Comp Online; Argatroban. (2009). Accessed 13 June 2012.
  86. 86.
    Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20:318–29.PubMedCrossRefGoogle Scholar
  87. 87.
    Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy. 2000;20:756–70.PubMedCrossRefGoogle Scholar
  88. 88.
    Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am. 2000;14:445–57. x.PubMedCrossRefGoogle Scholar
  89. 89.
    Matsuo T, Koide M, Kario K. Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation. Artif Organs. 1997;21:1035–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Dager WE, Gosselin RC, Yoshikawa R, Owings JT. Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation. Ann Pharmacother. 2004;38:598–601.PubMedCrossRefGoogle Scholar
  91. 91.
    Deitcher SR, Topoulos AP, Bartholomew JR, Kichuk-Chrisant MR. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr. 2002;140:264–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Maher J, Lapierre L, Schreiner G, Geiger M, Westervelt F. Regional heparinization for hemodialysis. N Engl J Med. 1963;268:451–6.CrossRefGoogle Scholar
  93. 93.
    Monchi M, Berghmans D, Ledoux D, Canivet J-L, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260–5.PubMedCrossRefGoogle Scholar
  94. 94.
    Brophy P, Somers M, Baum M, et al. Multi-centre evaluation of anticoagulation in patients receiving Continuous Renal Replacement Therapy (CRRT). Nephrol Dial Transplant. 2005;20:1416–21.PubMedCrossRefGoogle Scholar
  95. 95.
    Oudemans-van Straaten HM, Wester JPJ, de Pont ACJM, Schetz MRC. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med. 2006;32:188–202.PubMedCrossRefGoogle Scholar
  96. 96.
    Kikura M, Lee MK, Safon RA, Bailey JM, Levy JH. The effects of milrinone on platelets in patients undergoing cardiac surgery. Anesth Analg. 1995;81:44–8.PubMedGoogle Scholar
  97. 97.
    Rao A. Acquired qualitative platelet disorders. In: Colman R, Clowes A, George J, Hirsch J, Marder V, (eds.), Hemostasis and thrombosisl; basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 905–19.Google Scholar
  98. 98.
    Monagle P, Andrew M. Hemorrhagic and thromboembolic complications during infancy and childhood. In: Colman R, Hirsch J, Marder V, Salzman E, (eds.), Hemostasis and thrombosis; basic principles and clinical practice. 3rd ed. Philadlphia: Lippincott Williams & Wilkins; 1994. p. 815–37.Google Scholar
  99. 99.
    Arun B, Kessler C. Clinical manifestations and therapy of the hemophiliac. In: Colman R, Hirsch J, Marder V, Salzman E, (eds.), Hemostasis and thrombosis; basic principles and clinical practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1994. p. 815–24.Google Scholar
  100. 100.
    Sadler J, Mlinder M. von willebrand disease: diagnosis, classification, and treatment. In: Colman R, Hirsch J, Marder V, Salzman E, (eds.), Hemostasis and thrombosis; basic principles and clinical practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1994. p. 1032–43.Google Scholar
  101. 101.
    Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011;154:516–22.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883–90.PubMedCrossRefGoogle Scholar
  103. 103.
    MacLaren R, Weber LA, Brake H, Gardner MA, Tanzi M. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes. Transfusion. 2005;45:1434–42.PubMedCrossRefGoogle Scholar
  104. 104.
    Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke. 2005;36:74–9.PubMedCrossRefGoogle Scholar
  105. 105.
    Edmunds L. Hemostatic problems in surgical patients. In: Colman R, Hirsch J, Marder V, Salzman E, (eds.), Hemostasis and thrombosis; basic principles and clinical practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1994. p. 1032–43.Google Scholar
  106. 106.
    Dempfle C-E, Wurst M, Smolinski M, et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost. 2004;91:812–8.PubMedGoogle Scholar
  107. 107.
    Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. (ISTH) SSoDICDotISoTaH. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.PubMedGoogle Scholar
  108. 108.
    Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2005;16:69–74.PubMedCrossRefGoogle Scholar
  109. 109.
    Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for Disseminated Intravascular Coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am J Hematol. 2003;74:17–22.PubMedCrossRefGoogle Scholar
  110. 110.
    Dhainaut J-F, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924–33.PubMedCrossRefGoogle Scholar
  111. 111.
    Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625–31.PubMedCrossRefGoogle Scholar
  112. 112.
    Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34:625–31.PubMedCrossRefGoogle Scholar
  113. 113.
    Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005;128:2864–75.PubMedCrossRefGoogle Scholar
  114. 114.
    Barton P, Kalil AC, Nadel S, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. 2004;113:7–17.PubMedCrossRefGoogle Scholar
  115. 115.
    Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007;369:836–43.PubMedCrossRefGoogle Scholar
  116. 116.
    Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev. 2012;3:CD004388.Google Scholar
  117. 117.
    Lindon JN, McManama G, Kushner L, Merrill EW, Salzman EW. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces? Blood. 1986;68:355–62.PubMedGoogle Scholar
  118. 118.
    Laufer N, Merin G, Grover NB, Pessachowicz B, Borman JB. The influence of cardiopulmonary bypass on the size of human platelets. J Thorac Cardiovasc Surg. 1975;70:727–31.PubMedGoogle Scholar
  119. 119.
    Uniyal S, Brash JL. Patterns of adsorption of proteins from human plasma onto foreign surfaces. Thromb Haemost. 1982;47:285–90.PubMedGoogle Scholar
  120. 120.
    Anderson HL, Cilley RE, Zwischenberger JB, Bartlett RH. Thrombocytopenia in neonates after extracorporeal membrane oxygenation. ASAIO Trans. 1986;32:534–7.PubMedCrossRefGoogle Scholar
  121. 121.
    Edmunds LH, Ellison N, Colman RW, et al. Platelet function during cardiac operation: comparison of membrane and bubble oxygenators. J Thorac Cardiovasc Surg. 1982;83:805–12.PubMedGoogle Scholar
  122. 122.
    Kestin AS, Valeri CR, Khuri SF, et al. The platelet function defect of cardiopulmonary bypass. Blood. 1993;82:107–17.PubMedGoogle Scholar
  123. 123.
    Major TC, Brant DO, Burney CP, et al. The hemocompatibility of a nitric oxide generating polymer that catalyzes S-nitrosothiol decomposition in an extracorporeal circulation model. Biomaterials. 2011;32:5957–69.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Major TC, Brant DO, Reynolds MM, et al. The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer. Biomaterials. 2010;31:2736–45.PubMedCrossRefGoogle Scholar
  125. 125.
    Mangano DT, Tudor IC, Dietzel C, Group MSoPIR, Foundation IRaE. The risk associated with aprotinin in cardiac surgery. New Engl J Med. 2006;354:353–65.PubMedCrossRefGoogle Scholar
  126. 126.
    Annich G, Miskulin J. Coagulation, anticoagulation and the interaction of blood and artificial surfaces. In: Van Meurs K, Lally K, Peek G, Zwischenberger J, (eds.), ECMO extracorporeal cardiopulmonary support in critical care. 3rd ed. Ann Arbor: Extracorporeal Life Support Organization; 2005. p. 29–58.Google Scholar
  127. 127.
    Harrington L, Hufnagel JM. Heparin-induced thrombocytopenia and thrombosis syndrome: a case study. Heart Lung. 1990;19:93–8.PubMedGoogle Scholar
  128. 128.
    MacLean JA, Moscicki R, Bloch KJ. Adverse reactions to heparin. Ann Allergy. 1990;65:254–9.PubMedGoogle Scholar
  129. 129.
    Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–5.PubMedCrossRefGoogle Scholar
  130. 130.
    Mullen MP, Wessel DL, Thomas KC, et al. The incidence and implications of anti-heparin-platelet factor 4 antibody formation in a pediatric cardiac surgical population. Anesth Analg. 2008;107:371–8.PubMedCrossRefGoogle Scholar
  131. 131.
    Risch L, Fischer JE, Schmugge M, Huber AR. Association of anti-heparin platelet factor 4 antibody levels and thrombosis in pediatric intensive care patients without thrombocytopenia. Blood Coagul Fibrinolysis. 2003;14:113–6.PubMedCrossRefGoogle Scholar
  132. 132.
    Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics. 2002;109:E10.PubMedCrossRefGoogle Scholar
  133. 133.
    George J. Platelet kinetics and pathophysiology of thrombocytopenia. In: Colman R, Hirsch J, Marder V, Clowes A, George J, (eds.), Hemostats and thrombosis; basic principles and clinical practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 447–59.Google Scholar
  134. 134.
    Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004;30:273–83.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Division of Critical Care Medicine, Department of PediatricsVanderbilt University School of MedicineNashvilleUSA
  2. 2.Department of Pediatrics and Communicable DiseasesUniversity of Michigan School of MedicineAnn ArborUSA

Personalised recommendations